MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study.

BACKGROUND In patients with prostate cancer who are deemed to be at intermediate or high risk of having nodal metastases, invasive diagnostic pelvic lymph-node dissection (PLND) is the gold standard for the detection of nodal disease. However, a new lymph-node-specific MR-contrast agent ferumoxtran-10 can detect metastases in normal-sized nodes (ie, <8 mm in size) by use of MR lymphoangiography (MRL). In this prospective, multicentre cohort study, we aimed to compare the diagnostic accuracy of MRL with up-to-date multidetector CT (MDCT), and test the hypothesis that a negative MRL finding obviates the need for a PLND. METHODS We included consecutive patients with prostate cancer who had an intermediate or high risk (risk of >5% according to routinely used nomograms) of having lymph-node metastases. All patients were assessed by MDCT and MRL, and underwent PLND or fine-needle aspiration biopsy. Imaging results were correlated with histopathology. The primary outcomes were sensitivity, specificity, accuracy, NPV, and PPV of MRL and MDCT. This study is registered with ClinicalTrials.gov, number NCT00185029. FINDINGS The study was done in 11 hospitals in the Netherlands between April 8, 2003, and April 19, 2005. 375 consecutive patients were included. 61 of 375 (16%) patients had lymph-node metastases. Sensitivity was 34% (21 of 61; 95% CI 23-48) for MDCT and 82% (50 of 61; 70-90) for MRL (McNemar's test p<0.05). Specificity was 97% (303 of 314; 94-98) for MDCT and 93% (291 of 314; 89-95) for MRL. Positive predictive value (PPV) was 66% (21 of 32; 47-81) for MDCT and 69% (50 of 73; 56-79) for MRL. Negative predictive value (NPV) was 88% (303 of 343; 84-91) for MDCT and 96% (291 of 302; 93-98) for MRL (McNemar's test p<0.05). Of the 61 patients with lymph-node metastases, 50 were detected by MRL, of which 40 (80%) had metastases in normal-sized lymph nodes. The high sensitivity and NPV of MRL imply that in patients with a negative MRL, the chance of positive lymph nodes is less than 11/302 (4%). INTERPRETATION MRL had significantly higher sensitivity and NPV than MDCT for patients with prostate cancer who had intermediate or high risk of having lymph-node metastases. In such patients, after a negative MRL, the post-test probability of having lymph-node metastases is low enough to omit a PLND.

[1]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[2]  R. Weissleder,et al.  A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. , 2005, Urology.

[3]  Ralph Weissleder,et al.  Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. , 2003, The New England journal of medicine.

[4]  D Jacqmin,et al.  Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles--initial clinical experience. , 1998, Radiology.

[5]  W A Murphy,et al.  Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. , 1984, Radiology.

[6]  W. Yuh,et al.  Initial clinical experience with dextran-coated superparamagnetic iron oxide for detection of lymph node metastases in patients with head and neck cancer. , 1994, Radiology.

[7]  M. Banerjee,et al.  Lymph node size does not correlate with the presence of prostate cancer metastasis. , 1999, Urology.

[8]  Alan W Partin,et al.  Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. , 2007, Urology.

[9]  A. Haese*,et al.  Health‐insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer , 2007, BJU international.

[10]  A. Olukotun,et al.  Phase I clinical evaluation of a new iron oxide MR contrast agent , 1994, Journal of magnetic resonance imaging : JMRI.

[11]  G. Muir,et al.  Laparoscopic pelvic lymph node dissection allows significantly more accurate staging in “high‐risk” prostate cancer compared to MRI or CT , 2003, Scandinavian journal of urology and nephrology.

[12]  E. Adang,et al.  The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. , 2008, Clinical radiology.

[13]  P. Narayan,et al.  Utility of preoperative serumprostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer , 1994 .

[14]  J. Witjes,et al.  Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. , 1996, AJR. American journal of roentgenology.

[15]  M. Harisinghani,et al.  Regional lymph node staging using lymphotropic nanoparticle enhanced magnetic resonance imaging with ferumoxtran-10 in patients with penile cancer. , 2005, The Journal of urology.

[16]  B. Seifert,et al.  Preoperative breast cancer staging: MR imaging of the axilla with ultrasmall superparamagnetic iron oxide enhancement. , 2002, Radiology.

[17]  A. Darzi,et al.  Diagnostic precision of nanoparticle-enhanced MRI for lymph-node metastases: a meta-analysis. , 2006, The Lancet. Oncology.

[18]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[19]  F. Freiha,et al.  Utility of preoperative serum prostate-specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer. , 1994, Urology.

[20]  A L Baert,et al.  Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. , 1994, Radiology.

[21]  M. Meng,et al.  When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis. , 2000, Journal of Urology.

[22]  D. Bostwick,et al.  Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. , 1994, The Journal of urology.

[23]  D. Bostwick,et al.  Risk of prostate carcinoma death in patients with lymph node metastasis , 2001, Cancer.

[24]  K. Eichler,et al.  Superparamagnetic iron oxide-enhanced MR imaging of head and neck lymph nodes. , 2002, Radiology.

[25]  J. Petros,et al.  Evaluation of staging lymphadenectomy in prostate cancer. , 1998, Urology.

[26]  P. Carroll,et al.  Original Articles: Prostate Cancer: The Use and Accuracy of Cross-Sectional Imaging and Fine Needle Aspiration Cytology for Detection of Pelvic Lymph Node Metastases Before Radical Prostatectomy , 1995 .

[27]  O. Halvorsen,et al.  Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer. , 1998, Scandinavian journal of urology and nephrology.

[28]  C. Olsson,et al.  Sensitivity of computed tomography in evaluation of pelvic lymph node metastases from carcinoma of bladder and prostate. , 1983, Urology.

[29]  J. Montie.  Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. , 2005, The Journal of urology.

[30]  R. Lufkin,et al.  Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neck. , 1994, AJNR. American journal of neuroradiology.

[31]  M. Bellin,et al.  Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography , 2003, Abdominal Imaging.

[32]  H. Miyake,et al.  Quantitative Detection of Micrometastases in Pelvic Lymph Nodes in Patients with Clinically Localized Prostate Cancer by Real-time Reverse Transcriptase-PCR , 2007, Clinical Cancer Research.

[33]  J. Triller,et al.  Die computertomographische Stadieneinteilung beim Prostatakarzinom , 1982 .

[34]  P. Carroll,et al.  The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy. , 1995, The Journal of urology.

[35]  J. Bishoff,et al.  Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection. , 1995, Urology.

[36]  M. Kattan.  Re: Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy gleason score (Partin Tables) based on cases from 2000 to 2005. , 2007, European urology.

[37]  M. Harisinghani,et al.  Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  H. Hricak,et al.  Magnetic resonance imaging of the lymph nodes: comparison with CT. , 1984, Radiology.

[39]  K. Miller,et al.  Does the molecular staging in pelvic lymph nodes improve the detection of relevant prostate cancer metastases? An assessment after 6 years , 2007, BJU international.

[40]  D. Khayat,et al.  Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. , 1994, Radiology.

[41]  F. Burkhard,et al.  The role of lymphadenectomy in prostate cancer , 2005, Nature Clinical Practice Urology.